PFE

VACCINES FOR CHILDREN

Medicare and healthcare policy issues as they relate to drug pricing. Oppose IRA, PREP Act and vaccine liability. General issues with tax reform and foreign tax issues. Issues related to drug consolidation.

Drug pricing and prescription digital therapeutics

Provide guidance and strategic counsel with regard to regulations and legislation that could impact the pharmaceutical industry generally and/or Pfizer specifically.

General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; drug importation; and drug shortages. Drug pricing proposals. The 340B program. Pharmacy benefit manager reform proposals, issues related to headache and migraine. P.L. 119-21. Tax issues affecting the pharmaceutical industry including international tax; implementation of PL 119-21. Vaccine excise tax issues and VICP. Medicare payment issues and Medicaid issues. Medicare Part D. Drug pricing proposals. Protecting Seniors Through Immunization Act. Pharmacy benefit manager reform proposals. H.R. 1, "One Big Beautiful Bill Act", issues related to biopharmaceutical issues Prescription drug pricing issues, particularly related to MFN. P.L. 119-21. Issues related to pharmaceutical manufacturing and development, trade and tariffs; potential tariff actions under Section 232 of the Trade Act of 1962. Policies impacting post pandemic public health emerge

Issues related to FY27 health appropriations Issues related to 340B Program Issues related to drug pricing

Issues related to drug development and pricing, generally vaccine safety and access, generally the 340B program, Issues related to pharmacy benefit managers, generally. H.R. 5509, the Safe Step Act Direct-to-Patient Prescription Drug Purchase Platforms Most Favored Nation drug pricing 340B HHS Pilot Program Model

Issues related to FDA regulation of pharmaceuticals. Drug pricing and Medicare, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041; Affordable Prescriptions for Patients Act. Vaccine Policy, Coverage and Access and the Vaccine Injury Compensation Fund. H.R.2214 - DRUG Act. Issues related to tariff and trade policy. International Supply Chain. Issues related to tariff and trade policy.

Intellectual Property Protections Vaccine Coverage Pediatric Immunization Schedule Vaccine Injury Compensation Program Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients H.R. 7837 - Most Favored Patient Act of 2026 Lyme Disease Issues 340B Issues Counterfeit Drugs Inflation Reduction Act (IRA) Prescription Drug User Fee Act (PDUFA) Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage H.R. 5509 - Safe Step Act S. 2903 - Safe Step Act S. 3510 - Biosimilar Inspection Modernization Act of 2025 Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Prescription Drug User Fee Act (PDUFA) 340B Issues Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage PBM Reform Counterfeit Drugs P.L. 117-169 - Inflation Reduction Act (IRA) of 2022 Drug Pricing Medicare/Medicaid Issues International Supply Chain Market Access Most Fa

Issues related to tariff and trade policy. Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program. Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patie